• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Kronos Bio Inc. (Amendment)

    2/13/23 3:23:40 PM ET
    $KRON
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KRON alert in real time by email
    SC 13G/A 1 SEC13G_Filing.htm SEC SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1 )*

                

    Kronos Bio, Inc.


    (Name of Issuer)

    Common Stock


    (Title of Class of Securities)

    50107A104


    (CUSIP Number)

    December 30, 2022


    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X] Rule 13d-1(b)
    [ ] Rule 13d-1(c)
    [ ] Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.)


    CUSIP No. 50107A104

    1. NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

    Capital World Investors
    95-1411037
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 0
    6. SHARED VOTING POWER 0
    7. SOLE DISPOSITIVE POWER 0
    8. SHARED DISPOSITIVE POWER 0
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0 Beneficial ownership disclaimed pursuant to Rule 13d-4
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.0%
    12. TYPE OF REPORTING PERSON

    IA

    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    


    Item 1.
    (a) Name of Issuer
    Kronos Bio, Inc.
    (b) Address of Issuer's Principal Executive Offices
    1300 So. El Camino Real, Suite 300, San Mateo, CA 94402
    Item 2.
    (a) Name of Person Filing
    Capital World Investors
    (b) Address of Principal Business Office or, if None, Residence
    333 SOUTH HOPE STREET, 55TH FLOOR, LOS ANGELES, CALIFORNIA 90071
    (c) Citizenship
    N/A
    (d) Title of Class of Securities
    Common Stock
    (e) CUSIP Number
    50107A104
    Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
    (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
    (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e) [X] An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E);
    (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F);
    (g) [ ] A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G);
    (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).
    Item 4. Ownership.
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a) Amount Beneficially Owned:
    0 **
    (b) Percent of Class:
    0.0%
    (c) Number of shares as to which such person has:
    (i) sole power to vote or to direct the vote 0
    (ii) shared power to vote or to direct the vote 0
    (iii) sole power to dispose or to direct the disposition of 0
    (iv) shared power to dispose or to direct the disposition of 0
    **Capital World Investors ("CWI") is a division of Capital Research and Management Company ("CRMC"), as well as its investment management subsidiaries and affiliates Capital Bank and Trust Company, Capital International, Inc., Capital International Limited, Capital International Sarl, Capital International K.K., Capital Group Private Client Services, Inc., and Capital Group Investment Management Private Limited (together with CRMC, the "investment management entities"). CWI's divisions of each of the investment management entities collectively provide investment management services under the name "Capital World Investors." CWI is deemed to be the beneficial owner of 0 shares or 0.0% of the 56,898,374 shares believed to be outstanding.
    Item 5. Ownership of Five Percent or Less of Class.
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ X ]
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
    Not Applicable
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
    Not Applicable
    Item 8. Identification and Classification of Members of the Group.

    Not Applicable. This schedule is not being filed pursuant to Rule 13d-1(b)(1)(ii)(J) or Rule 13d-1(d).
    Item 9. Notice of Dissolution of Group.

    Not Applicable
    Item 10. Certification.

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Capital World Investors
    By: /s/ Erik A. Vayntrub
    Date: February 14, 2023
    Name: Erik A. Vayntrub
    Title: Senior Vice President and Senior Counsel, Fund Business Management Group, Capital Research and Management Company

    Get the next $KRON alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KRON

    DatePrice TargetRatingAnalyst
    11/14/2024$6.00 → $1.00Overweight → Neutral
    Piper Sandler
    11/14/2024Buy → Hold
    TD Cowen
    9/14/2022$12.00Buy
    Berenberg
    2/28/2022$50.00 → $30.00Overweight
    Piper Sandler
    11/10/2021$35.00 → $36.00Buy
    HC Wainwright & Co.
    10/20/2021Outperform
    Cowen
    6/24/2021$35.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $KRON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Administrative Officer Frisbee Allison

      4 - Kronos Bio, Inc. (0001741830) (Issuer)

      10/15/24 6:57:17 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Scientific Officer Lin Charles Y

      4 - Kronos Bio, Inc. (0001741830) (Issuer)

      10/15/24 6:55:36 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PRESIDENT & CEO Bischofberger Norbert W bought $733,801 worth of shares (615,518 units at $1.19) (SEC Form 4)

      4 - Kronos Bio, Inc. (0001741830) (Issuer)

      7/1/24 8:27:32 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Kronos downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Kronos from Overweight to Neutral and set a new price target of $1.00 from $6.00 previously

      11/14/24 7:43:21 AM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kronos downgraded by TD Cowen

      TD Cowen downgraded Kronos from Buy to Hold

      11/14/24 7:42:59 AM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Berenberg initiated coverage on Kronos with a new price target

      Berenberg initiated coverage of Kronos with a rating of Buy and set a new price target of $12.00

      9/14/22 7:25:57 AM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRON
    Financials

    Live finance-specific insights

    See more
    • Kronos Bio Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study at AACR-NCI-EORTC

      Demonstrated on-mechanism, single agent anti-tumor activity in heavily pre-treated patients with transcriptionally addicted solid tumors Showed manageable safety profile, with no grade 3/4 neutropenia, dose proportional exposure, dose-dependent target engagement, and 24-hour plasma half-life Dose escalation continues; dosing of patients at the 80 mg dose level is ongoing Enrollment ongoing in dose expansion phase in MYC-dependent and other transcriptionally addicted solid tumors, including lung, ovarian, and triple negative breast cancers Company to host conference call and webcast today at 4:30 PM ET with key opinion leader and KB-0742 trial investigator, Miguel Villalona-Calero, M.D.

      10/13/23 12:30:00 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13

      SAN MATEO, Calif., and CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that it will host a conference call and webcast on Friday, October 13, 2023, at 4:30 p.m. ET., followed by a Q&A session. The event will feature trial investigator, Miguel Villalona-Calero, M.D, Medical Oncologist and Director of Early Therapeutics, City of Hope, along with Kronos Bio management, who will discuss the current treatment landscape for patients with MYC-dependent solid tumors, provide an overview of KB-0742 and further discuss the poster to be presented at the AACR-NCI-EORTC Interna

      10/4/23 4:05:00 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kronos Bio Announces Prioritization of Clinical Portfolio to Focus on Lanraplenib and KB-0742

      Company to discontinue Phase 3 entospletinib trial for strategic reasons Enrollment continues for Phase 1/2b trial in relapsed/refractory AML with Kronos Bio's next generation SYK inhibitor, lanraplenib Company on track to provide KB-0742 update from ongoing Phase 1/2 clinical trial in Q4 With $270.3 million in cash, cash equivalents and investments as of Sept. 30, 2022, Kronos Bio extends expected cash runway from Q4 2024 into Q2 2025 Conference call and webcast scheduled for today at 4:30 p.m. ET SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to transforming the lives of those affected by cancer, today

      11/8/22 4:05:00 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRON
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $KRON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • PRESIDENT & CEO Bischofberger Norbert W bought $733,801 worth of shares (615,518 units at $1.19) (SEC Form 4)

      4 - Kronos Bio, Inc. (0001741830) (Issuer)

      7/1/24 8:27:32 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PRESIDENT & CEO Bischofberger Norbert W bought $3,119,081 worth of shares (3,005,122 units at $1.04) (SEC Form 4)

      4 - Kronos Bio, Inc. (0001741830) (Issuer)

      6/12/24 7:23:55 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bischofberger Norbert W bought $1,470,395 worth of shares (1,731,056 units at $0.85), increasing direct ownership by 214% to 2,540,665 units (SEC Form 4)

      4 - Kronos Bio, Inc. (0001741830) (Issuer)

      11/17/23 5:41:27 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Kronos Bio Inc.

      SC 13G/A - Kronos Bio, Inc. (0001741830) (Subject)

      11/14/24 7:58:27 AM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Kronos Bio Inc.

      SC 13D/A - Kronos Bio, Inc. (0001741830) (Subject)

      7/2/24 9:01:03 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Kronos Bio Inc.

      SC 13D/A - Kronos Bio, Inc. (0001741830) (Subject)

      6/12/24 7:32:56 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRON
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right

      CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. ("Kronos Bio") (NASDAQ:KRON), a biotechnology company that has been developing small molecule therapeutics to address cancers and other diseases driven by deregulated transcription, today announced that it has entered into a definitive merger agreement (the "Merger Agreement") with Concentra Biosciences, LLC ( "Concentra"), whereby Concentra will acquire Kronos Bio for $0.57 in cash per share of Kronos Bio common stock ("Kronos Bio Common Stock"), plus one non-tradeable contingent value right ("CVR"), which represents the right to receive: (i) 50% of the net proceeds in the case of a disposition of the Company's product ca

      5/1/25 8:30:00 AM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results

      SAN MATEO, Calif., and CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a biopharmaceutical company, today reported fourth quarter and full year 2024 financial results. Fourth Quarter and Full Year 2024 Financial Results Cash, cash equivalents and investments: Cash, cash equivalents and investments as of December 31, 2024, were $112.4 million.R&D Expenses: Research and development expenses were $8.4 million for the fourth quarter of 2024, which includes non-cash stock-based compensation expense of $0.7 million. For the full year of 2024, research and development expenses were $48.7 million, which includes non-cash stock-based compensation expense o

      3/18/25 4:01:00 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kronos Bio Announces CEO Transition and Reduction in Force

      – Norbert Bischofberger, Ph.D., is stepping down from his role as President & CEO – – Deborah Knobelman, Ph.D., COO & CFO, is named President & Interim CEO – SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company developing small molecule therapeutics to address cancers and other diseases driven by deregulated transcription, today announced that its Board of Directors has appointed Deborah Knobelman, Ph.D., as President and Interim Chief Executive Officer, effective December 3, 2024. Dr. Knobelman will be the principal executive, financial and accounting officer. She is succeeding Norbert Bischofberger, Ph.D., who will step dow

      11/27/24 7:30:00 AM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRON
    Leadership Updates

    Live Leadership Updates

    See more

    $KRON
    SEC Filings

    See more
    • Kronos Bio Announces CEO Transition and Reduction in Force

      – Norbert Bischofberger, Ph.D., is stepping down from his role as President & CEO – – Deborah Knobelman, Ph.D., COO & CFO, is named President & Interim CEO – SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company developing small molecule therapeutics to address cancers and other diseases driven by deregulated transcription, today announced that its Board of Directors has appointed Deborah Knobelman, Ph.D., as President and Interim Chief Executive Officer, effective December 3, 2024. Dr. Knobelman will be the principal executive, financial and accounting officer. She is succeeding Norbert Bischofberger, Ph.D., who will step dow

      11/27/24 7:30:00 AM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer

      SAN MATEO, Calif. and CAMBRIDGE, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced that it has appointed Deborah Knobelman, Ph.D., as Chief Operating Officer and Chief Financial Officer effective June 3, 2024. Dr. Knobelman will oversee the finance, accounting, business development, investor relations and corporate strategy functions. "I'm excited to have Deb join our team. She is a proven life sciences leader, and her strategic vision will play a critical role in shaping the future of Kronos Bio. As we continue to

      5/21/24 8:15:00 AM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vicore Expands and Strengthens its Board of Directors

      STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas

      5/14/24 2:20:00 AM ET
      $KRON
      $MACK
      $MXCT
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
      Biotechnology: Laboratory Analytical Instruments
    • SEC Form SC 14D9 filed by Kronos Bio Inc.

      SC 14D9 - Kronos Bio, Inc. (0001741830) (Subject)

      5/15/25 1:09:14 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Kronos Bio Inc.

      10-Q - Kronos Bio, Inc. (0001741830) (Filer)

      5/8/25 4:21:04 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC14D9C filed by Kronos Bio Inc.

      SC14D9C - Kronos Bio, Inc. (0001741830) (Subject)

      5/1/25 9:22:44 AM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care